Anti-tumor effects of dual PI3K-HDAC inhibitor CUDC-907 on activation of ROS-IRE1α-JNK-mediated cytotoxic autophagy in esophageal cancer

被引：0
|
作者：
Zheng Jian
Yichao Han
Wentian Zhang
Chengqiang Li
Wei Guo
Xijia Feng
Bin Li
Hecheng Li
机构：
[1] Shanghai Jiao Tong University School of Medicine,Department of Thoracic Surgery, Ruijin Hospital
[2] Tong Ji University School of Medicine,Department of Thoracic Surgery, Shanghai Pulmonary Hospital
[3] Shanghai Jiao Tong University School of Medicine,Shanghai Institute of Immunology, Department of Immunology and Microbiology
来源：
Cell & Bioscience | / 12卷
关键词：
PI3K-Akt; HDAC; CUDC-907; Autophagy; Esophageal cancer; CDX;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 24 条
  • [1] Anti-tumor effects of dual PI3K-HDAC inhibitor CUDC-907 on activation of ROS-IRE1α-JNK-mediated cytotoxic autophagy in esophageal cancer
    Jian, Zheng
    Han, Yichao
    Zhang, Wentian
    Li, Chengqiang
    Guo, Wei
    Feng, Xijia
    Li, Bin
    Li, Hecheng
    CELL AND BIOSCIENCE, 2022, 12 (01):
  • [2] Antitumor activity of CUDC-907, a dual PI3K and HDAC inhibitor, in hematological cancer models
    Rudi, Bao
    Wang, Dagong
    Qu, Hui
    Yin, Ling
    Zifcak, Brian
    DellaRocca, Steven
    Xu, Guang-Xin
    Borek, Mylissa
    Samson, Maria
    Atoyan, Ruzanna
    Poll, Anne
    Wang, Jing
    Zhai, Hai-Xaio
    Lai, Cheng-Jung
    Pepicelli, Carmen
    Cai, Xiong
    Qian, Changgeng
    CANCER RESEARCH, 2012, 72
  • [3] Dual function HDAC and PI3K inhibitor, CUDC-907 affects cancer cells and the tumor microenvironment in hematological malignancies
    Ma, Anna W.
    Atoyan, Ruzanna
    Younes, Anas
    Flinn, Ian W.
    Oki, Yasuhiro
    Copeland, Amanda
    Berdeja, Jesus G.
    Laliberte, Robert
    Viner, Jaye
    Samson, Maria Elena S.
    Dellarocca, Steven
    Yi, Ling
    Borek, Mylissa
    Zifcak, Brian
    Xu, Guangxin
    Wang, Jing
    CANCER RESEARCH, 2014, 74 (19)
  • [4] CUDC-907, a Dual HDAC and PI3K Inhibitor, Potentially Targets Cancer Cells and The Microenvironment In Hematological Malignancies
    Wang, Jing
    Pursell, Natalie
    Ma, Anna
    Atoyan, Ruzanna
    Samson, Maria
    Borek, Mylissa
    DellaRocca, Steven
    Yin, Ling
    Wang, Da-gong
    Zifcak, Brian
    Xu, Guang-xin
    Voi, Maurizio
    Lai, Cheng-Jung
    BLOOD, 2013, 122 (21)
  • [5] Antitumor activity and mechanism of resistance of the novel HDAC and PI3K dual inhibitor CUDC-907 in pancreatic cancer
    Liu, Shuang
    Zhao, Shoujing
    Dong, Yang
    Wang, Tingting
    Niu, Xiaojia
    Zhao, Lijing
    Wang, Guan
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 87 (03) : 415 - 423
  • [6] Antitumor activity and mechanism of resistance of the novel HDAC and PI3K dual inhibitor CUDC-907 in pancreatic cancer
    Shuang Liu
    Shoujing Zhao
    Yang Dong
    Tingting Wang
    Xiaojia Niu
    Lijing Zhao
    Guan Wang
    Cancer Chemotherapy and Pharmacology, 2021, 87 : 415 - 423
  • [7] CUDC-907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: Antitumour activity and molecular mechanism of action
    Hu, Cheng
    Xia, Hongyan
    Bai, Shanshan
    Zhao, Jianlei
    Edwards, Holly
    Li, Xinyu
    Yang, Yanrong
    Lyu, Jing
    Wang, Guan
    Zhan, Yang
    Dong, Yan
    Ge, Yubin
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2020, 24 (13) : 7239 - 7253
  • [8] The dual HDAC and PI3K inhibitor, CUDC-907, inhibits tumor growth and stem-like properties by suppressing PTX3 in neuroblastoma
    Li, Mengzhen
    Hu, Yang
    Wang, Juan
    Xu, Yanjie
    Hong, Ye
    Zhang, Li
    Luo, Qiuyun
    Zhen, Zijun
    Lu, Suying
    Huang, Junting
    Zhu, Jia
    Zhang, Yizhuo
    Que, Yi
    Sun, Feifei
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2024, 64 (02)
  • [9] The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer
    Ma, Liying
    Bian, Xing
    Lin, Wenchu
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2020, 39 (01)
  • [10] The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer
    Liying Ma
    Xing Bian
    Wenchu Lin
    Journal of Experimental & Clinical Cancer Research, 39
123